Wall Street analysts expect Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Rating) to post earnings per share (EPS) of $0.55 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Actinium Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is $1.28. Actinium Pharmaceuticals reported earnings of ($0.25) per share […]
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing […]
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm presently has a $6.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.02% from the […]